National Immunoglobulin Governance Program Performance Improvement Strategy 2019-2022

A strategy to improve use and management of immunoglobulin

At its meeting on 14 March 2019, the Jurisdictional Blood Committee endorsed the National Immunoglobulin Governance Program Performance Improvement Strategy 2019-2022 (the Strategy). This document describes a strategy to improve the prescription, use and management of government-funded Ig products accessed in accordance with the National Policy: Access to Government Funded Immunoglobulin Products in Australia. It has been developed to communicate the  intended approach to enhance various aspects of the National Immunoglobulin Governance Program and improve performance through focussed activities. Five pathways are described in this document, each comprising projects and activities which will be implemented in an effort to meet objectives in five performance areas.

The 5 key performance management areas which set the objectives for this strategy are:

  1. Provision of Ig reflects appropriate clinical practice
  2. Uniform compliance with the National Policy
  3. Local Ig governance arrangements are robust and align with relevant standards, guidelines and legislative requirements
  4. Service delivery provided to support appropriate management and use of Ig (by the NBA and agencies contracted by the NBA) is efficient and effective
  5. Collection of data supports future work

The pathways that will drive improvement across the performance areas listed above are:

  1. Education and Support
  2. Communications and Relationships
  3. Program Assurance and Policy Compliance
  4. Knowledge Development
  5. Enhancement of Policy and Access Arrangements

The approach outlined in this document will further strengthen governance, drive improvement in the prescription, use and management of government-funded Ig products and support the program to continue to deliver against agreed objectives over the coming years.

The Strategy promotes a nationally consistent approach to monitoring performance and identifying obstacles and challenges to performance. As part of the Strategy, the NBA will develop tools and mechanisms to promote continuous improvement amongst all those involved in the prescription, management and use of government-funded Ig products. Where issues are identified, the NBA will develop and implement solutions.

Cover image of National Immunoglobulin Governance Program Performance Improvement Strategy 2019-20 to 2021-22  (pdf)Cover image of National Immunoglobulin Governance Program Performance Improvement Strategy 2019-20 to 2021-22  (docx) 

Keep up to date

Keep up to date with the latest Immunoglobulin Governance updates - create a BloodPortal account and from the home page click on ‘My Subscriptions’ and ‘Subscribe’ to Immunoglobulin. The latest update is available at Ig Governance Criteria and Progress Updates.

For further information

Please contact the National Blood Authority on 13 000 IG GOV (13 000 44 468) or email IgGovernance@blood.gov.au.